Developer docs
API playgroundTry for free, no card

Search company profiles

Koite Health

Full company profile

uuid0002kv4

Namestring
Koite Health
Legal namestring
Koite Health Oy
Websiteurl
koitehealth.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Koite Health Oy, founded in September 2018 in Espoo, Finland, is a venture-backed medical technology company that develops and commercializes light-activated antibacterial devices for oral healthcare. Its core platform, branded KOITE®, uses dual-light photodynamic therapy (PDT) combining 405nm violet light and 810nm near-infrared light to activate an indocyanine green (ICG) photosensitizer delivered via the Lumorinse mouthrinse tablet, generating singlet oxygen that selectively destroys pathogenic oral bacteria and biofilms without harming healthy tissue. The commercial product portfolio includes Lumoral (CE-marked Class IIa home-use PDT device for adults), Lumoral Junior (pediatric version for ages 4–12), and Oncolum (photobiomodulation device targeting oral mucositis in oncology patients), supported by the Lumoral 2.0 companion mobile application.

The company sells hardware (Lumoral and Lumoral Junior devices) to dental professionals and directly to consumers via its own e-commerce storefront and pharmacy chains, then generates recurring revenue through monthly subscriptions for Lumorinse consumable tablets. Distribution is multi-country and partner-led: Unident covers the Nordics, Megagen Iberia covers Spain and Latin America, white cross covers the DACH region, Elixiria Trading covers the UAE, HealthHub Pharma covers Poland, ProImplant covers Estonia and Latvia, Innodent covers Thailand, and in Sweden Apotek Hjärtat and Apoteket AB provide pharmacy retail. The company reports 40,000+ end users, 2M+ cumulative treatments delivered, an 88% recommendation rate among dental professionals, and 81% monthly subscriber retention on Lumorinse. It is EU MDR Class IIa certified (November 2025), ISO 13485 and ISO 9001 certified, holds CE marking (CE 0598), and is approved by the Australian TGA.

Koite Health operates in a stated €8.4 billion EU/US/China TAM for prevention and treatment of periodontal and peri-implant diseases. The company has raised over €9 million across three disclosed funding rounds and appointed Peter Rådqvist, a 30-year dental implant industry veteran (Nobel Biocare, Straumann, Zimmer Biomet, Bactiguard AB), as CEO in October 2025 to lead international expansion into France, Portugal, the USA, and adjacent indications including wound care.

Short descriptiontext

Koite Health Oy is a Finnish medical technology company that develops light-activated photodynamic therapy devices (Lumoral, Lumoral Junior, Oncolum) for home-use antibacterial oral care, combining dual-light PDT with a consumable Lumorinse tablet sold by subscription through dental clinics, pharmacies, and e-commerce across 40+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEspoo, Finland
HQ citystring
Espoo
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral health devices, photodynamic therapy, antibacterial oral care, medical device manufacturing, dental health technology
Industry1 code
PRIMARYCRADAMAA
Oral Care Products (Toothpaste, Mouthwash, Dental Floss, Whitening)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code2 codes
  • Dental Equipment and Supplies Manufacturing339114
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Dental Equipment & Supplies3843
  • Surgical & Medical Instruments & Apparatus3841
Product category
Oral Health Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Lumoral Device Sales
TypeHardware Sales
Description

One-time hardware sales of Lumoral and Lumoral Junior PDT devices to dental clinics and directly to consumers via pharmacies and e-commerce. Initial product sales drive customer acquisition.

2Lumorinse Consumable Subscriptions
TypeSubscription Recurring
Description

Recurring monthly subscriptions for Lumorinse ICG-activated mouthwash tablets, driven by the Lumoral 2.0 app's 81% monthly subscriber retention rate. App tracks treatments and automatically triggers consumable reorder reminders.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels9 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Lumoral
Description

Light-activated antibacterial oral care product for treating and preventing gum disease and oral infections. CE-marked Class IIa medical device.

koitehealth.com
+3 more records
Core offering1 text field

Koite Health manufactures and sells the Lumoral and Lumoral Junior home-use antibacterial photodynamic therapy (PDT) devices, the Oncolum medical device for oral mucositis management, and the Lumorinse ICG-activated mouthrinse tablets used with the Lumoral device. Products are CE-marked Class IIa medical devices sold direct-to-consumer via e-commerce and pharmacy chains, and B2B via dental professional distributors and clinics across 40+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 99.9% kill rate against Streptococcus mutans in 2 minutes (in vitro study)
+4 more records
Product overview1 text field

Koite Health offers a portfolio of light-activated antibacterial medical devices for oral health care. The core product is Lumoral, a CE-marked Class IIa dual-light photodynamic therapy device that combines with Lumorinse mouthrinse tablets for home-based antibacterial treatment. The portfolio includes Lumoral Junior for pediatric patients, Oncolum for oral mucositis management in cancer patients, and a companion mobile application. The company is developing wound healing applications using the same technology platform. The business model combines device sales with recurring revenue from consumable Lumorinse tablets, with distribution through dental professionals, pharmacies, and local partners across European and international markets.

Product and service3 records
1Lumoral
CategoryOral Health Medical Device (Adult)
Description

Light-activated antibacterial oral care device for adults using dual-light photodynamic therapy (aPDT) combining blue (405nm) and near-infrared (810nm) light with Lumorinse mouthrinse tablets to eliminate harmful plaque bacteria while preserving normal oral flora. CE-marked Class IIa medical device for home use as an adjunct to professional mechanical plaque removal for periodontitis, gingivitis, and peri-implantitis patients.

2Lumoral Junior
CategoryOral Health Medical Device (Pediatric)
Description

Pediatric version of the Lumoral PDT oral care device adapted for children aged 4-12 years, using the same dual-light photodynamic therapy technology as the adult device. Indicated for children with elevated caries risk, orthodontic appliances, or early-stage gingivitis. CE-marked Class IIa medical device covered by the November 2025 EU MDR certification.

3Oncolum
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeTechnology or Integration
Description

Finnish software and technology consultancy that developed Koite Health's digital ecosystem, including the Lumoral 2.0 mobile application. Partnership covers mobile app development and digital platform integration.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Nordic dental distributor with close to 300 employees across Sweden, Norway, Denmark, and Finland. Serves as the primary dental channel partner for Lumoral device distribution to dental clinics throughout the Nordics.

3Megagen Iberia
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Dental distributor covering Spain and Latin American markets for Lumoral device distribution to dental professionals and clinics.

4Elixiria Trading
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Dental and medical products distributor operating in the UAE and broader Middle East region, distributing Koite Health's oral care devices.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Pharmaceutical and dental distributor for Poland, distributing Lumoral products through dental clinics and pharmacies.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Dental implant care distributor covering Estonia and Latvia, distributing Lumoral for peri-implantitis management in dental implant patients.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Dental distributor for Thailand market, distributing Koite Health's oral PDT products to dental professionals.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Sweden's largest pharmacy chain, offering Lumoral products through both online and physical pharmacy locations, enabling direct patient access to Koite Health's oral care devices.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Swedish government-owned pharmacy chain. Lumoral products planned for physical store rollout starting February 2026, representing significant Swedish pharmacy market access.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Dental products distributor covering Germany, Austria, and Switzerland (DACH region), distributing Lumoral devices to dental professionals.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

US-based DTC oral care subscription brand (toothbrushes, whitening, floss). Comparable direct-to-consumer subscription motion targeting consumers seeking premium at-home oral care, though in adjacent categories rather than PDT.

TypeEmerging player
Description

Swedish-listed infection prevention company developing anti-adhesion coating technology for medical devices. Highly comparable thematically — Nordic infection-prevention medtech focused on reducing antibiotic reliance — and overlapping with Koite's AMR value proposition.

TypeBroad incumbent
Description

Colgate is the dominant global oral care brand across toothpaste, mouthwash, and adjunct devices. Comparable end-customer (consumer oral hygiene), comparable recurring-revenue model via consumables, and a clear strategic threat if it enters light-based antibacterial therapy.

TypeBroad incumbent
Description

Philips Sonicare is the global leader in premium home-use electric oral care devices. It is the most relevant broad incumbent competitor — overlapping end-customer (home-use oral hygiene), overlapping channel (dental professional recommendation + retail), and with sufficient R&D resources to potentially enter home-use antibacterial PDT.

TypeDirect peer
Description

Swiss premium oral care brand (Curaprox) selling consumer toothbrushes, interdental brushes, and adjunct products through dental professionals and pharmacy. Direct comparable in premium home-use oral care sold via dentist recommendation + pharmacy channels.

TypeEmerging player
Description

US-based DTC oral care subscription brand offering electric toothbrushes, refill heads, toothpaste, and floss. Comparable subscription + app-driven engagement model and consumer oral care positioning, though without antibacterial or PDT technology.

TypeBroad incumbent
Description

Oral-B is a leading global premium home-use oral care device brand (electric toothbrushes, including the iO connected platform). Comparable end-customer (mass-market + premium oral hygiene) and direct overlap in retail pharmacy and dental professional channels.

TypeDirect peer
Description

Spanish oral care company (Bexident, Interprox) selling mouthwashes, toothpastes, and interdental products through dental professionals and pharmacy. Comparable size and distribution model (clinics + pharmacy), with overlapping mouthwash product category to Lumorinse.

TypeDirect peer
Description

Ondine Biomedical develops photodynamic therapy (PDT) products for nasal and oral infection prevention, including MRSA decolonization. The closest technology comparable — both firms are commercial-stage PDT antimicrobial companies targeting infection prevention, including in oral care settings.

10TePe
TypeDirect peer
Description

Swedish-headquartered oral hygiene company selling interdental brushes, toothbrushes, and specialty oral care products primarily through dental professionals. Direct comparable in premium oral care distributed via dental channel and pharmacy across Europe.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Koite Health

Oral Health Medical Deviceskoitehealth.com

Koite Health Oy is a Finnish medical technology company that develops light-activated photodynamic therapy devices (Lumoral, Lumoral Junior, Oncolum) for home-use antibacterial oral care, combining dual-light PDT with a consumable Lumorinse tablet sold by subscription through dental clinics, pharmacies, and e-commerce across 40+ countries.

What Koite Health does

Koite Health Oy, founded in September 2018 in Espoo, Finland, is a venture-backed medical technology company that develops and commercializes light-activated antibacterial devices for oral healthcare. Its core platform, branded KOITE®, uses dual-light photodynamic therapy (PDT) combining 405nm violet light and 810nm near-infrared light to activate an indocyanine green (ICG) photosensitizer delivered via the Lumorinse mouthrinse tablet, generating singlet oxygen that selectively destroys pathogenic oral bacteria and biofilms without harming healthy tissue. The commercial product portfolio includes Lumoral (CE-marked Class IIa home-use PDT device for adults), Lumoral Junior (pediatric version for ages 4–12), and Oncolum (photobiomodulation device targeting oral mucositis in oncology patients), supported by the Lumoral 2.0 companion mobile application.

The company sells hardware (Lumoral and Lumoral Junior devices) to dental professionals and directly to consumers via its own e-commerce storefront and pharmacy chains, then generates recurring revenue through monthly subscriptions for Lumorinse consumable tablets. Distribution is multi-country and partner-led: Unident covers the Nordics, Megagen Iberia covers Spain and Latin America, white cross covers the DACH region, Elixiria Trading covers the UAE, HealthHub Pharma covers Poland, ProImplant covers Estonia and Latvia, Innodent covers Thailand, and in Sweden Apotek Hjärtat and Apoteket AB provide pharmacy retail. The company reports 40,000+ end users, 2M+ cumulative treatments delivered, an 88% recommendation rate among dental professionals, and 81% monthly subscriber retention on Lumorinse. It is EU MDR Class IIa certified (November 2025), ISO 13485 and ISO 9001 certified, holds CE marking (CE 0598), and is approved by the Australian TGA.

Koite Health operates in a stated €8.4 billion EU/US/China TAM for prevention and treatment of periodontal and peri-implant diseases. The company has raised over €9 million across three disclosed funding rounds and appointed Peter Rådqvist, a 30-year dental implant industry veteran (Nobel Biocare, Straumann, Zimmer Biomet, Bactiguard AB), as CEO in October 2025 to lead international expansion into France, Portugal, the USA, and adjacent indications including wound care.

Koite Health firmographics

Firmographics
Name
Koite Health
Legal name
Koite Health Oy
Website
https://koitehealth.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Koite Health Oy is a Finnish medical technology company that develops light-activated photodynamic therapy devices (Lumoral, Lumoral Junior, Oncolum) for home-use antibacterial oral care, combining dual-light PDT with a consumable Lumorinse tablet sold by subscription through dental clinics, pharmacies, and e-commerce across 40+ countries.
Ownership category
akta.pro rank

Koite Health industry classification

Industry
Product category
Oral Health Medical Devices
NAICS
Dental Equipment and Supplies Manufacturing (339114), Surgical and Medical Instrument Manufacturing (339112)
SIC
Dental Equipment & Supplies (3843), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYCRADAMAA
Oral Care Products (Toothpaste, Mouthwash, Dental Floss, Whitening)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Oral health devices
  • Photodynamic therapy
  • Antibacterial oral care
  • Medical device manufacturing
  • Dental health technology

Where Koite Health is headquartered

Location

Headquarters

HQ city
Espoo
HQ country
Finland
HQ region
Europe

Offices1 record

Markets served

Koite Health business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

  1. Lumoral Device Sales: One-time hardware sales of Lumoral and Lumoral Junior PDT devices to dental clinics and directly to consumers via pharmacies and e-commerce. Initial product sales drive customer acquisition.
  2. Lumorinse Consumable Subscriptions: Recurring monthly subscriptions for Lumorinse ICG-activated mouthwash tablets, driven by the Lumoral 2.0 app's 81% monthly subscriber retention rate. App tracks treatments and automatically triggers consumable reorder reminders.

Go-to-market motion2 records

Distribution channels9 records

Marketing channels4 records

Koite Health product offering

Product offering

Core offering

Koite Health manufactures and sells the Lumoral and Lumoral Junior home-use antibacterial photodynamic therapy (PDT) devices, the Oncolum medical device for oral mucositis management, and the Lumorinse ICG-activated mouthrinse tablets used with the Lumoral device. Products are CE-marked Class IIa medical devices sold direct-to-consumer via e-commerce and pharmacy chains, and B2B via dental professional distributors and clinics across 40+ countries.

Product overview

Koite Health offers a portfolio of light-activated antibacterial medical devices for oral health care. The core product is Lumoral, a CE-marked Class IIa dual-light photodynamic therapy device that combines with Lumorinse mouthrinse tablets for home-based antibacterial treatment. The portfolio includes Lumoral Junior for pediatric patients, Oncolum for oral mucositis management in cancer patients, and a companion mobile application. The company is developing wound healing applications using the same technology platform. The business model combines device sales with recurring revenue from consumable Lumorinse tablets, with distribution through dental professionals, pharmacies, and local partners across European and international markets.

Differentiator

Problem solved

Functional benefit

Brands

  • Lumoral: Light-activated antibacterial oral care product for treating and preventing gum disease and oral infections. CE-marked Class IIa medical device.
  • Lumoral Junior
  • Lumorinse
  • Oncolum

Products and services

  • Lumoral Light-activated antibacterial oral care device for adults using dual-light photodynamic therapy (aPDT) combining blue (405nm) and near-infrared (810nm) light with Lumorinse mouthrinse tablets to eliminate harmful plaque bacteria while preserving normal oral flora. CE-marked Class IIa medical device for home use as an adjunct to professional mechanical plaque removal for periodontitis, gingivitis, and peri-implantitis patients.
  • Lumoral Junior Pediatric version of the Lumoral PDT oral care device adapted for children aged 4-12 years, using the same dual-light photodynamic therapy technology as the adult device. Indicated for children with elevated caries risk, orthodontic appliances, or early-stage gingivitis. CE-marked Class IIa medical device covered by the November 2025 EU MDR certification.
  • Oncolum

Quantifiable outcome

  • 99.9% kill rate against Streptococcus mutans in 2 minutes (in vitro study)
  • +4 more outcomes

Companies that use Koite Health

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Koite Health technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Koite Health partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core.

  • ReaktorcoreTechnology or IntegrationFinnish software and technology consultancy that developed Koite Health's digital ecosystem, including the Lumoral 2.0 mobile application. Partnership covers mobile app development and digital platform integration.
  • UnidentcoreChannel Partner/ Reseller/ DistributorNordic dental distributor with close to 300 employees across Sweden, Norway, Denmark, and Finland. Serves as the primary dental channel partner for Lumoral device distribution to dental clinics throughout the Nordics.
  • Megagen IberiacoreChannel Partner/ Reseller/ DistributorDental distributor covering Spain and Latin American markets for Lumoral device distribution to dental professionals and clinics.
  • Elixiria TradingcoreChannel Partner/ Reseller/ DistributorDental and medical products distributor operating in the UAE and broader Middle East region, distributing Koite Health's oral care devices.
  • HealthHub PharmacoreChannel Partner/ Reseller/ DistributorPharmaceutical and dental distributor for Poland, distributing Lumoral products through dental clinics and pharmacies.
  • ProImplantcoreChannel Partner/ Reseller/ DistributorDental implant care distributor covering Estonia and Latvia, distributing Lumoral for peri-implantitis management in dental implant patients.
  • Innodent TradingcoreChannel Partner/ Reseller/ DistributorDental distributor for Thailand market, distributing Koite Health's oral PDT products to dental professionals.
  • Apotek HjärtatcoreChannel Partner/ Reseller/ DistributorSweden's largest pharmacy chain, offering Lumoral products through both online and physical pharmacy locations, enabling direct patient access to Koite Health's oral care devices.
  • Apoteket ABcoreChannel Partner/ Reseller/ DistributorSwedish government-owned pharmacy chain. Lumoral products planned for physical store rollout starting February 2026, representing significant Swedish pharmacy market access.
  • white cross GmbHcoreChannel Partner/ Reseller/ DistributorDental products distributor covering Germany, Austria, and Switzerland (DACH region), distributing Lumoral devices to dental professionals.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Koite Health competitors and assessment

Company assessment

Emerging players

  • BURST Oral Care: US-based DTC oral care subscription brand (toothbrushes, whitening, floss). Comparable direct-to-consumer subscription motion targeting consumers seeking premium at-home oral care, though in adjacent categories rather than PDT.
  • Bactiguard: Swedish-listed infection prevention company developing anti-adhesion coating technology for medical devices. Highly comparable thematically — Nordic infection-prevention medtech focused on reducing antibiotic reliance — and overlapping with Koite's AMR value proposition.
  • Quip: US-based DTC oral care subscription brand offering electric toothbrushes, refill heads, toothpaste, and floss. Comparable subscription + app-driven engagement model and consumer oral care positioning, though without antibacterial or PDT technology.

Broad incumbents

  • Colgate-Palmolive: Colgate is the dominant global oral care brand across toothpaste, mouthwash, and adjunct devices. Comparable end-customer (consumer oral hygiene), comparable recurring-revenue model via consumables, and a clear strategic threat if it enters light-based antibacterial therapy.
  • Philips (Sonicare): Philips Sonicare is the global leader in premium home-use electric oral care devices. It is the most relevant broad incumbent competitor — overlapping end-customer (home-use oral hygiene), overlapping channel (dental professional recommendation + retail), and with sufficient R&D resources to potentially enter home-use antibacterial PDT.
  • Procter & Gamble (Oral-B / iO): Oral-B is a leading global premium home-use oral care device brand (electric toothbrushes, including the iO connected platform). Comparable end-customer (mass-market + premium oral hygiene) and direct overlap in retail pharmacy and dental professional channels.

Direct peers

  • Curaden (Curaprox): Swiss premium oral care brand (Curaprox) selling consumer toothbrushes, interdental brushes, and adjunct products through dental professionals and pharmacy. Direct comparable in premium home-use oral care sold via dentist recommendation + pharmacy channels.
  • Dentaid: Spanish oral care company (Bexident, Interprox) selling mouthwashes, toothpastes, and interdental products through dental professionals and pharmacy. Comparable size and distribution model (clinics + pharmacy), with overlapping mouthwash product category to Lumorinse.
  • Ondine Biomedical: Ondine Biomedical develops photodynamic therapy (PDT) products for nasal and oral infection prevention, including MRSA decolonization. The closest technology comparable — both firms are commercial-stage PDT antimicrobial companies targeting infection prevention, including in oral care settings.
  • TePe: Swedish-headquartered oral hygiene company selling interdental brushes, toothbrushes, and specialty oral care products primarily through dental professionals. Direct comparable in premium oral care distributed via dental channel and pharmacy across Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Koite Health social profiles

Digital presence

Koite Health compliance and trust

Trust signal

Compliance5 records

Koite Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Koite Health leadership team

Management profile

Number of profiles

Profiles10 records

Koite Health funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Koite Health M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Koite Health

What does Koite Health do?

Koite Health manufactures and sells the Lumoral and Lumoral Junior home-use antibacterial photodynamic therapy (PDT) devices, the Oncolum medical device for oral mucositis management, and the Lumorinse ICG-activated mouthrinse tablets used with the Lumoral device. Products are CE-marked Class IIa medical devices sold direct-to-consumer via e-commerce and pharmacy chains, and B2B via dental professional distributors and clinics across 40+ countries.

Is Koite Health a public or private company?

Koite Health is a private company. It is classified as venture growth investor backed and is currently operating.

When was Koite Health founded?

Koite Health was founded in 2018. It employs 11 to 50 people.

Where is Koite Health based?

Koite Health is headquartered in Espoo, Finland, in the Europe region.

How does Koite Health make money?

Two revenue lines are on record. Lumoral Device Sales are the primary driver. The others are lumorinse Consumable Subscriptions.

Who are Koite Health's main competitors?

Emerging players on record are BURST Oral Care, Bactiguard and Quip. Broad incumbents are Colgate-Palmolive, Philips (Sonicare) and Procter & Gamble (Oral-B / iO). Direct peers are Curaden (Curaprox), Dentaid, Ondine Biomedical and TePe.

Does Koite Health have an API?

No public API is recorded for Koite Health.

What industry is Koite Health in?

Koite Health's product category is Oral Health Medical Devices. Its primary akta.pro industry code is CRADAMAA, Oral Care Products (Toothpaste, Mouthwash, Dental Floss, Whitening). Its NAICS code is 339114 and its SIC code is 3843.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comBrånemark Osseointegration Centers and Koite Health enter research collaboration on preventive care in implant dentistryKoite Health and the Associated Brånemark Osseointegration Centers announced a research collaboration on light-activated antibacterial therapy for implant preventive care. The project will examine how Lumoral home-use devices can be integrated into structured preventive pathways for peri-implant health. The collaboration aims to build clinical evidence and professional education on prevention.news.cision.comUnident and Koite Health partner to bring Lumoral light-activated oral care to dental clinics across the NordicsUnident and Koite Health announced a collaboration to make Lumoral, a light-activated home-use oral care device, available to dental clinics across the Nordic market. The partnership aims to integrate Lumoral into clinic-led preventive care pathways, including implant and periodontal treatments, to support patients between visits.news.cision.comNew Multicenter Randomized Trial: Daily Home-Applied Dual-Light Therapy Improves Key Periodontitis Outcomes When Added to Standard CareA multicenter randomized trial of 40 adults with periodontitis found that daily at-home Lumoral dual-light therapy added to standard care significantly reduced bleeding, plaque, and deep pockets over six months. The findings align with a larger HOPE-CP study, suggesting the device complements professional periodontal care.news.cision.comKoite Health Secures EU MDR Quality Management System Certification for Lumoral Phototherapy DevicesKoite Health Oy has received EU Quality Management System Certification under the European Medical Device Regulation for its Class IIa phototherapy devices, Lumoral and Lumoral Junior, used for treating and preventing oral diseases caused by dental plaque. The certification confirms the devices meet stringent safety and performance standards, authorizing the company to continue affixing the CE mark and maintaining market access across Europe. The Finnish medical technology company, founded in 2018, now plans to conduct a Post-Market Clinical Follow-up study specifically for pediatric use of Lumoral Junior.InvesdorInvesting in MedTech companiesThe article outlines the benefits of investing in MedTech companies through the Invesdor crowdfunding platform, highlighting potential for high returns and positive social impact. It features specific examples of funded companies including Koite Health, Monidor, and Aplagon, detailing their respective technologies and market growth. The text serves as an informational guide for investors interested in early-stage healthcare technology ventures.NatureHome-use oral health-enhancing deviceLumoral, a home-use oral health device developed by Koite Health Ltd, is an antibacterial, light-activated treatment used with regular brushing. It targets bacteria causing gum disease and halitosis, reducing periodontitis-causing bacteria and plaque. The device is a Class II medical device with CE approval and is available in the UK.InvesdorFunding: Koite Health OyKoite Health Oy is raising growth capital through an equity offering to support the international rollout of its Lumoral antibacterial photodynamic treatment and fund clinical studies for new applications. The company has sold over 10,000 units since 2020 and is expanding into European markets including Germany, Italy, and the UK with a pre-money valuation of approximately €20 million.KoitehealthKoite Health Oy raised more than 4 million euros in the autumn share issue – Koite HealthKoite Health Oy, a health technology company based in Espoo, Finland, successfully raised over 4.1 million euros through a funding round held from October to December 2023. The raised funds will support the growth of its Lumoral® oral care product and expand its international market presence following successful launches in several European countries. The company aims to continue its growth trajectory after doubling its revenues in 2023 and exceeding 20,000 Lumoral devices sold.LumoralKoite Health Oy raised more than 4 million euros in the autumn share issueKoite Health Oy, a health technology company based in Espoo, Finland, successfully raised over 4.1 million euros in a funding round from domestic and foreign investors between October and December 2023. The proceeds are intended to support the growth of their Lumoral® oral care product and to develop new applications as the company continues to expand into various European markets. The successful share issue addressed current growth financing challenges while enabling Koite Health to double its revenues in 2023.